Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan

By sjmartinez • March 20, 2024

Heist RS, Sands J, Bardia A, Shimizu T, Lisberg A, Krop I, Yamamoto N, Kogawa T, Al-Hashimi S, Fung SSM, Galor A, Pisetzky F, Basak P, Lau C, Meric-Bernstam F. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev. 2024 Mar 11;125:102720. doi: 10.1016/j.ctrv.2024.102720. Epub ahead of print. PMID: 38502995.

Tags: Adverse events, Dato-DXd, Datopotamab deruxtecan, Hematology/Oncology, HR+/HER2− breast cancer, NSCLC, Publications, TNBC

Related Posts

Dose-escalated stereotactic body radiotherapy re-irradiation in patients with recurrent head and neck cancer: a prospective phase 2 study using automated non-coplanar volumetric modulated arc therapy

Nikitas J, Ma TM, Cook K, Woods K, Kishan AU, Reddy VK, Hegde JV, John MS, Chai-Ho W, Wong D, Chu FI, Felix C, Tenn[...]

Stereotactic Body Radiation Therapy Utilization Trends for Stage I Non-Small Cell Lung Cancer

Sakowitz S, Tupper HI, Benjamin LN, Oh S, He T, Ronaghi R, Channick CL, Rosenberg BJ, Salehi-Rad R, Smith MI, Bando JM, Young TJ, Barjaktarvic[...]

Liquid Biopsy of Circulating Tumor Cells and DNA in the Context of PSMA Radiopharmaceutical Therapy

Holzgreve A, Mona CE, Kimura K, Li X, Zhu Y, Tseng HR, Lee JK, Drakaki A, Garraway IP, Rettig MB, Calais J, Salavati A. Liquid[...]